In this study, we found that inhibition of BCL6 in activated CD8 T cells increased the expression of glucose transporter GLUT3, thereby maintaining glycolysis, and indicating that retarding T-cell exhaustion in tumor conditions is a plausible therapeutic strategy. The gene discussed is BCL6; the disease is neoplasm.